ProCE Banner Activity

HAVEN 4 Preliminary Analysis: Pharmacokinetic Run-in Cohort of Phase III Study of Q4W Emicizumab in Hemophilia A

Slideset Download
Conference Coverage
Preliminary analysis finds that pharmacokinetic parameters of SC emicizumab Q4W were promising and consistent with previous observations.

Released: December 11, 2017

Expiration: December 10, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Novartis Pharmaceuticals Corporation